Literature DB >> 26519335

Predictive Value of Admission Hemoglobin A1c on Inpatient Glycemic Control and Response to Insulin Therapy in Medicine and Surgery Patients With Type 2 Diabetes.

Francisco J Pasquel1, Ricardo Gomez-Huelgas2, Isabel Anzola1, Festus Oyedokun1, J Sonya Haw1, Priyathama Vellanki1, Limin Peng3, Guillermo E Umpierrez4.   

Abstract

Entities:  

Year:  2015        PMID: 26519335      PMCID: PMC4657617          DOI: 10.2337/dc15-1835

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
High hemoglobin A1c (A1C) levels are associated with poor clinical outcomes in hospitalized patients. Recent guidelines have recommended performing A1C measurements in hospitalized patients with hyperglycemia to differentiate between stress hyperglycemia and undiagnosed diabetes, to assess the level of glycemic control prior to admission in patients with diabetes, and to tailor appropriate diabetes therapy regimens at hospital discharge (1). To study the predictive role of admission A1C on inpatient glycemic control in medical and surgical hospitalized patients with type 2 diabetes, we combined inpatient data from four randomized controlled trials of patients treated with a basal-bolus insulin regimen (2–5). We adopted the definition of optimal glycemic control as a combination of blood glucose (BG) levels below 180 mg/dL without hypoglycemia (BG <70 mg/dL) after 24 h of insulin therapy. Logistic regression models were used to evaluate the predictive role of three categories of A1C (≤7%, >7–9%, and >9%) on inpatient glycemic control and hypoglycemia. We adjusted for potential predictors including age, race, sex, BMI, duration of diabetes, creatinine, and hospital setting via multivariate logistic regression models. Among 402 patients (mean ± SD admission BG 209 ± 88 mg/dL, A1C 8.6 ± 2.4%), a total of 134 (33.3%), 127 (31.5%), and 139 (34.6%) patients had an admission A1C ≤7%, >7–9%, and >9%, respectively. Mean hospital BG was 152 ± 35, 161 ± 29, and 178 ± 38 mg/dL in patients with A1C ≤7%, >7–9%, and >9%, respectively (P < 0.001). Patients with A1C ≤7% received a lower total daily insulin dose (28 ± 20 units/day) compared with patients with A1C >7–9% (36 ± 21 units/day) and >9% (40 ± 23 units/day) (P < 0.001). Patients with higher A1C levels had lower odds of having optimal glucose control of ≥70 mg/dL and <180 mg/dL compared with patients with A1C ≤7% (A1C >7–9%, odds ratio 0.45 [95% CI 0.22–0.92]; A1C >9%, 0.37 [0.17–0.75]), as well as lower but nonsignificant odds of hypoglycemia (A1C >7–9%, 0.57 [0.23–1.39]; and A1C >9%, 0.47 [0.17–1.24]) (Table 1).
Table 1

Association of hypoglycemia and glycemic control with categories of admission A1C

Unadjusted modelModel 1aModel 2b
Hypoglycemia (<70 mg/dL)
 A1C ≤7%1 (reference)1 (reference)1 (reference)
 A1C >7–9%0.74 (0.39–1.4)0.68 (0.35–1.31)0.57 (0.23–1.39)
 A1C >9%0.48 (0.24–0.95)0.46 (0.23–0.94)0.47 (0.17–1.24)
All BG <180 mg/dL (>24 h)c
 A1C ≤7%1 (reference)1 (reference)1 (reference)
 A1C >7–9%0.39 (0.23–0.65)0.40 (0.23–0.68)0.39 (0.19–0.81)
 A1C >9%0.29 (0.18–0.49)0.29 (0.17–0.51)0.34 (0.16–0.71)
All BG ≥70 and <180 mg/dL (>24 h)c
 A1C ≤7%1 (reference)1 (reference)1 (reference)
 A1C >7–9%0.42 (0.25–0.71)0.44 (0.26–0.75)0.45 (0.22–0.92)
 A1C >9%0.32 (0.19–0.53)0.33 (0.19–0.57)0.37 (0.17–0.75)

Data are odds ratio (95% CI).

Model 1: adjusted for age, race, sex, and BMI.

Model 2: model 1 + adjustment for duration of diabetes, creatinine, and hospital setting.

Effect estimated after 24 h of therapy with basal-bolus therapy.

Association of hypoglycemia and glycemic control with categories of admission A1C Data are odds ratio (95% CI). Model 1: adjusted for age, race, sex, and BMI. Model 2: model 1 + adjustment for duration of diabetes, creatinine, and hospital setting. Effect estimated after 24 h of therapy with basal-bolus therapy. It is well established that both hyperglycemia and hypoglycemia are associated with worse outcomes in hospitalized patients (1). Our results highlight the role of A1C beyond its current utilization to assess previous glycemic control or to tailor regimens at hospital discharge in patients with diabetes. A1C can estimate the risk of hypoglycemia and glycemic control in patients treated with insulin therapy and could potentially help redefine the best insulin initiation strategies on admission. A scheduled basal-bolus regimen with a total daily insulin dose calculated based on patient’s body weight is currently recommended, but the role of A1C on these estimations should be further investigated. In summary, our results show that A1C level on admission is an excellent predictor of glycemic control and response to insulin treatment with basal-bolus during hospitalization in patients with type 2 diabetes. Patients with higher A1C levels on admission were less likely to achieve glycemic control compared with patients admitted with A1C ≤7%, despite an incremental adjustment of insulin therapy. Our results suggest that A1C on admission to the hospital should be considered in the estimation of initial total daily dose insulin requirements.
  5 in total

1.  Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline.

Authors:  Guillermo E Umpierrez; Richard Hellman; Mary T Korytkowski; Mikhail Kosiborod; Gregory A Maynard; Victor M Montori; Jane J Seley; Greet Van den Berghe
Journal:  J Clin Endocrinol Metab       Date:  2012-01       Impact factor: 5.958

2.  Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).

Authors:  Guillermo E Umpierrez; Dawn Smiley; Ariel Zisman; Luz M Prieto; Andres Palacio; Miguel Ceron; Alvaro Puig; Roberto Mejia
Journal:  Diabetes Care       Date:  2007-05-18       Impact factor: 19.112

3.  Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial.

Authors:  Guillermo E Umpierrez; Dawn Smiley; Kathie Hermayer; Amna Khan; Darin E Olson; Christopher Newton; Sol Jacobs; Monica Rizzo; Limin Peng; David Reyes; Ingrid Pinzon; Maria Eugenia Fereira; Vicky Hunt; Ashwini Gore; Marcos T Toyoshima; Vivian A Fonseca
Journal:  Diabetes Care       Date:  2013-02-22       Impact factor: 19.112

4.  Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery).

Authors:  Guillermo E Umpierrez; Dawn Smiley; Sol Jacobs; Limin Peng; Angel Temponi; Patrick Mulligan; Denise Umpierrez; Christopher Newton; Darin Olson; Monica Rizzo
Journal:  Diabetes Care       Date:  2011-01-12       Impact factor: 19.112

5.  Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 diabetes.

Authors:  Priyathama Vellanki; Rachel Bean; Festus A Oyedokun; Francisco J Pasquel; Dawn Smiley; Farnoosh Farrokhi; Christopher Newton; Limin Peng; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2015-02-09       Impact factor: 19.112

  5 in total
  15 in total

1.  THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF SITAGLIPTIN WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AT HOSPITAL DISCHARGE.

Authors:  Roma Y Gianchandani; Francisco J Pasquel; Daniel J Rubin; Kathleen M Dungan; Priyathama Vellanki; Heqiong Wang; Isabel Anzola; Patricia Gomez; Israel Hodish; Sangeeta Lathkar-Pradhan; Jennifer Iyengar; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2018-06       Impact factor: 3.443

2.  A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.

Authors:  Francisco J Pasquel; M Cecilia Lansang; Ameer Khowaja; M Agustina Urrutia; Saumeth Cardona; Bonnie Albury; Rodolfo J Galindo; Maya Fayfman; Georgia Davis; Alexandra Migdal; Priyathama Vellanki; Limin Peng; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2020-04-09       Impact factor: 19.112

3.  Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.

Authors:  Luis M Pérez-Belmonte; Julio Osuna-Sánchez; Mercedes Millán-Gómez; María D López-Carmona; Juan J Gómez-Doblas; Lidia Cobos-Palacios; Jaime Sanz-Cánovas; Miguel A Barbancho; José P Lara; Manuel Jiménez-Navarro; M Rosa Bernal-López; Ricardo Gómez-Huelgas
Journal:  Ann Med       Date:  2019-05-21       Impact factor: 4.709

Review 4.  Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?

Authors:  Francisco J Pasquel; Maya Fayfman; Guillermo E Umpierrez
Journal:  Curr Diab Rep       Date:  2019-07-29       Impact factor: 4.810

Review 5.  Timing of Insulin with Meals in the Hospital: a Systems Improvement Approach.

Authors:  Kathleen Dungan
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

Review 6.  The Emory University Perioperative Algorithm for the Management of Hyperglycemia and Diabetes in Non-cardiac Surgery Patients.

Authors:  Elizabeth W Duggan; Matthew A Klopman; Arnold J Berry; Guillermo Umpierrez
Journal:  Curr Diab Rep       Date:  2016-03       Impact factor: 4.810

7.  Report on Racial Disparities in Hospitalized Patients with Hyperglycemia and Diabetes.

Authors:  Maya Fayfman; Priyathama Vellanki; Anastasia-Stefania Alexopoulos; Lauren Buehler; Liping Zhao; Dawn Smiley; Sonya Haw; Jeff Weaver; Francisco J Pasquel; Guillermo E Umpierrez
Journal:  J Clin Endocrinol Metab       Date:  2016-01-06       Impact factor: 5.958

8.  Using a Diabetes Risk Score to Identify Patients Without Diabetes at Risk for New Hyperglycemia in the Hospital.

Authors:  Carlos E Mendez; Rebekah J Walker; Aprill Z Dawson; Kevin Lu; Leonard E Egede
Journal:  Endocr Pract       Date:  2021-04-19       Impact factor: 3.701

9.  Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients.

Authors:  Rajesh Garg; Brooke Schuman; Shelley Hurwitz; Cheyenne Metzger; Shreya Bhandari
Journal:  BMJ Open Diabetes Res Care       Date:  2017-03-29

Review 10.  Management of Inpatient Hyperglycemia and Diabetes in Older Adults.

Authors:  Guillermo E Umpierrez; Francisco J Pasquel
Journal:  Diabetes Care       Date:  2017-04       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.